awmsg logo



elosulfase alfa (Vimizim®)


Reference No. 1084

Publication date:
24/03/2016


Appraisal information

elosulfase alfa (Vimizim®) 1 mg/ml concentrate for solution for infusion


Company: BioMarin Europe Ltd
BNF category: Nutrition and blood
NMG meeting date: Not scheduled
AWMSG meeting date: 24/02/2016
   
   
Submission Type: NICE HST
Status: Recommended
Advice No: Not available
Ministerial ratification: 16/03/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

The National Institute for Health and Care Excellence (NICE) published advice in December 2015 in relation to elosulfase alfa (Vimizim®) for the treatment of patients with mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA). At their meeting on 24th February 2016 AWMSG supported the adoption and implementation of this advice within NHS Wales (refer to the minutes of meetings). The Minister for Health and Social Services has subsequently agreed that the NICE HST advice for elosulfase alfa (Vimizim®) should be implemented within NHS Wales. Refer to the NICE website for full guidance including any specific restrictions on the use of the technology.